Aveanna Healthcare Holdings (AVAH) is back on traders radar after the stock reached a new all time high, supported by four consecutive positive earnings surprises and a Zacks Rank of #2.

At a share price of US$13.32, Aveanna Healthcare Holdings has seen strong momentum over the past few months, with a 30 day share price return of 36.62% and a 90 day share price return of 85.77%. The 1 year total shareholder return of 66.50% and very large 3 year total shareholder return suggest that recent enthusiasm has built on a longer recovery story, helped by the August follow on equity offering and management’s upcoming appearance at the Deutsche Bank 2026 Healthcare Summit, even though the stock slipped 3.62% on the day.

Scan momentum stories like Aveanna Healthcare Holdings and see how they compare with our hand picked 44 high quality undervalued stocks that pair strong trends with solid fundamentals.

Bulls point to Aveanna Healthcare Holdings hitting fresh highs and beating earnings expectations, while bears flag the recent equity raise and past profit pressure. The valuation section next shows which case the current numbers lean toward.

Most Popular Narrative: 34% Overvalued

The most followed narrative currently estimates Aveanna Healthcare Holdings fair value at $9.95, which sits well below the latest close at $13.32. That gap hinges on a detailed set of growth, margin and valuation assumptions that investors may want to understand before relying on recent share price strength.

Accelerating adoption of home-based healthcare and increasing patient preference for in-home care are driving strong and sustained demand for Aveanna's services, which management repeatedly noted remains robust and outstrips the company's current capacity, supporting the potential for significant future revenue growth as the company hires and retains more caregivers.

Want to see what sits behind this valuation gap? The narrative leans on steady revenue expansion, slimmer margins and a higher future earnings multiple. Curious which assumptions really move that $9.95 fair value?

Based on that framework, Aveanna Healthcare Holdings screens as overvalued relative to the narrative fair value, with the current price sitting above both the $9.95 estimate and the analyst target range centered around the same level. The entire approach applies a discount rate of 7.88% to bring those future cash flows and earnings back to today, which is what drives the 34% overvaluation estimate at the current $13.32 share price.

Result: Fair Value of $9.95 (OVERVALUED)

However, Aveanna Healthcare Holdings still faces pressure from high variable rate debt and heavy reliance on Medicaid and Medicare reimbursement, both of which could challenge the current narrative.

Another View on Aveanna Healthcare Holdings Valuation

While the narrative fair value for Aveanna Healthcare Holdings comes out at $9.95 and flags the stock as overvalued, the SWS DCF model points in the opposite direction. On that measure, AVAH at $13.32 screens as trading about 53% below an estimated fair value of $28.42. Which framework do you trust more when the signals clash this sharply?

Next Steps

Mixed signals around Aveanna Healthcare Holdings can feel confusing, so act while this is fresh and build your own view using our breakdown of 3 key rewards and 3 important warning signs.

Looking for more Aveanna Healthcare Holdings investment ideas?

If the Aveanna Healthcare Holdings story has your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your next move.

• Scan for potential mispriced opportunities by reviewing the 44 high quality undervalued stocks that combine strong fundamentals with attractive valuations.
• Strengthen the defensive side of your portfolio by checking the 74 resilient stocks with low risk scores that aim for more resilient risk profiles.
• Spot companies that mainstream investors may have overlooked by using the 19 high quality undiscovered gems with solid underlying data.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.